

ESMO Advanced Course on Cholangiocarcinoma: Where are we going?

PROGRAMME

**ESMO
ADVANCED COURSE**

**BARCELONA SPAIN
21-22 NOVEMBER 2025**

CO-CHAIRS

Julien Edeline, France

Angela Lamarca, Spain

esmo.org

ESMO ADVANCED COURSE PROGRAMME

CHOLANGIOCARCINOMA: WHERE ARE WE GOING?

Barcelona, Spain
21-22 November 2025

CO-CHAIRS Julien Edeline, France
Angela Lamarca, Spain

SPEAKERS Ana Landa Magdalena, Spain
Maeve Lowery, Ireland
Teresa Macarulla, Spain
David Malka, France
Victor Moreno, Spain
Andrea Ruzzenente, Italy
Anna Saborowski, Germany
Giulia Tesini, Italy
Ana Vivancos, Spain

LEARNING OBJECTIVES

- To understand diagnostic challenges and clinical and molecular differences in cholangiocarcinoma
- To review adjuvant and palliative treatment strategies in patients with cholangiocarcinoma
- To discuss the role of surgery and other locoregional therapy for cholangiocarcinoma
- To investigate the role of immunotherapy for the management of cholangiocarcinoma
- To explore currently available and novel targeted therapies and treatment options for advanced disease

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This educational programme has been supported by



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 21 November 2025

- 09:00-09:10** **Welcome and introduction**
- 10' Welcome and learning objectives
Julien Edeline, FR and Angela Lamarca, ES
- 09:10-10:35** **Session 1 – Understanding biliary tract tumours**
- 15' What are biliary tract tumours (primary site, epidemiology, and symptoms management)?
Teresa Macarulla, ES
- 15' Ampullary cancer
Ana Landa Magdalena, ES
- 15' The role of pathology and molecular testing
Ana Vivancos, ES
- 20' The role of centers of expertise (role for surgery, role for systemic therapy)
Teresa Macarulla, ES and Andrea Ruzzenente, IT
- 20' Discussion
- 10:35-11:05** **Coffee break**
- 11:05-12:10** **Session 2 – Locoregional and surgical therapies**
- 20' Locoregional therapy: Is it ready for the clinic?
Julien Edeline, FR
- 25' Biliary drainage, surgery and transplant
Andrea Ruzzenente, IT
- 20' Discussion
- 12:10-13:00** **Session 3 – Adjuvant and neoadjuvant treatment**
- 30' Adjuvant and neoadjuvant treatment
David Malka, FR
- 20' Discussion
- 13:00-14:00** **Lunch**
- 14:00-15:00** **Session 4 – The management of advanced disease: Chemotherapy and immunotherapy**
- 20' Chemotherapy – First line and second line: How is the field moving forward?
Angela Lamarca, ES
- 20' Immunotherapy: Rationale, current data, and upcoming studies
Julien Edeline, FR
- 20' Discussion
- 15:00-16:00** **Session 5 – The management of advanced disease: Targeted therapies and new treatment options**
- 20' Targeted therapies FGFR, IDH and HER2: Current data and compounds in advanced (phase II and beyond) stage of development
Maeve Lowery, IE

20'	Targeted therapies beyond FGFR, IDH and HER2: Current data and compounds in advanced (phase II and beyond) stage of development Anna Saborowski, DE
20'	Discussion
16:00-16:30	Coffee break
16:30-17:50	Session 6 – Bringing the latest science into patients care
10'	What can a phase I unit add to the management of BTC Victor Moreno, ES
15'	Ongoing clinical trials and status of drug approval Teresa Macarulla, ES
40'	Multidisciplinary tumour board Giulia Tesini, IT and Faculty
15'	Discussion
20:00	Networking dinner

Saturday, 22 November 2025

09:00-09:45	MDT case discussion Faculty
09:45-12:30	Workshop sessions Three parallel workshop sessions with 20 delegates in each group (Delegates will attend all 3 sessions on a rotational basis) 10' Introduction based on clinical cases presented by speakers 30' Discussion 5' Break Workshop 1 Locoregional disease Julien Edeline, FR and Andrea Ruzzenente, IT Workshop 2 Palliative chemotherapy (+/- immunotherapy) Angela Lamarca, ES and David Malka, FR Workshop 3 Molecular testing and targeted therapy Maeve Lowery, IE and Anna Saborowski, DE
10:30-11:00	Coffee break
11:00-12:30	Workshops continuation
12:30-13:00	Feedback on the workshops from each group
13:00-13:15	Synthesis and wrap-up Julien Edeline, FR and Angela Lamarca, ES
13:15-14:15	Lunch